Extraction of Gallium(III) with a New Azo Dye in The Presence or Absence of Xylometazoline Hydrochloride

Complex formation between Ga(III) and 6-hexyl-4-(2-thiazolylazo)resorcinol (HTAR, H2L) was studied in a water-chloroform medium, in the presence or absence of xylometazoline hydrochloride (XMH). Optimum conditions for the extraction of Ga(III) were found. In the presence of XMH, the extracted ion-associate has the formula (XMH+)[GaIIIL2], where HTAR is in its deprotonated form L2–. Some key extraction-spectrophotometric characteristics were determined: absorption maximum (521 nm), apparent molar absorptivity (5.8 × 104 dm3 mol–1 cm–1), limit of detection (18 ng cm–3), limit of quantitation (60 ng cm–3), extraction constant (LogK = 4.44), distribution ratio (LogD = 2.2) and fraction extracted (99.3 %). In the absence of XMH, the extracted chelate contains one deprotonated and one monoprotonated HTAR: [GaIII(HL–)(L2–)]. It has an absorption maximum at 523 nm and a shoulder at 580–590 nm. The pKa of HTAR (H2L ⇄ H+ + HL– equilibrium) was calculated (5.4) and the effect of foreign ions was studied. This work is licensed under a Creative Commons Attribution 4.0 International License

High-Temperature Surface Oxide Growth Kinetics of Al–Si–Zr Bulk Alloys and Ribbons

A typical modification technique of the functional properties of Al–Si based alloys is the addition of some third element in trace level. In the present work, ternary Al–Si–Zr bulk and ribbon alloys have been prepared. The kinetics of high-temperature surface oxidation has been studied by thermogravimetric method. It was found that at the start of the experiment the chemical reaction velocity is rate-controlling while for longer times the (oxygen) diffusion is the rate-controlling process. Activation energy of the two stages of oxidation has been obtained. Additional studies such as thermochemical analysis, optical and electron microscopy, and microhardness tests have been done

High-Temperature Surface Oxide Growth Kinetics of Al–Si–Zr Bulk Alloys and Ribbons

A typical modification technique of the functional properties of Al–Si based alloys is the addition of some third element in trace level. In the present work, ternary Al–Si–Zr bulk and ribbon alloys have been prepared. The kinetics of high-temperature surface oxidation has been studied by thermogravimetric method. It was found that at the start of the experiment the chemical reaction velocity is rate-controlling while for longer times the (oxygen) diffusion is the rate-controlling process. Activation energy of the two stages of oxidation has been obtained. Additional studies such as thermochemical analysis, optical and electron microscopy, and microhardness tests have been done

Preparation and Preliminary Evaluation of Silver-Modified Anodic Alumina for Biomedical Applications

The present study reports a specific method for preparation of silver-modified anodic alumina substrates intended for biomaterial applications. Al2O3 coatings were obtained by anodization of technically pure aluminum alloy in sulfuric acid electrolyte. Silver deposition into the pores of the anodic structures was carried out employing in situ thermal reduction for different time periods. The obtained coatings were characterized using scanning electron microscopy (SEM), potentiodynamic scanning after 168 h in 3.5% NaCl solution and bioassays with human fibroblast and NIH/3T3 cell lines. The modified alumina substrates demonstrated better biocompatibility compared to the control anodic Al2O3 pads indicated by increased percent cell survival following in vitro culture with human and mouse fibroblasts. The Ag-deposition time did not affect considerably the biocompatibility of the investigated anodic layers. SEM analyses indicated that mouse NIH/3T3 cells and human fibroblasts adhere to the silver-coated alumina substrates retaining normal morphology and ability to form cell monolayer. Therefore, the present studies demonstrate that silver coating of anodic alumina substrates improves their biocompatibility and their eventual biomedical application

Spectrophotometric Determination of Molybdenum(VI) as a Ternary Complex with 4-Nitrocatechol and Benzalkonium Chloride

A new liquid—liquid extraction system for molybdenum(VI) was studied. It contains 4-nitrocatechol (4NC) as a complexing chromogenic reagent and benzalkonium chloride (BZC) as a source of heavy cations (BZ+), which are prone to form chloroform-extractable ion-association complexes. The optimum conditions for the determination of trace molybdenum(VI) were found: concentrations of 4NC and BZC (7.5 × 10−4 mol dm−3 and 1.9 × 10−4 mol dm−3, respectively), acidity (3.75 × 10−2 mol dm−3 H2SO4), extraction time (3 min), and wavelength (439 nm). The molar absorptivity, limit of detection, and linear working range were 5.5 × 104 dm3 mol−1 cm−1, 5.6 ng cm−3, and 18.6–3100 μg cm−3, respectively. The effect of foreign ions was examined, and the developed procedure was applied to the analysis of synthetic mixtures and real samples (potable waters and steels). The composition of the extracted complex was 1:1:2 (Mo:4NC:BZ). Three possible structures of its anionic part [MoVI(4NC)O2(OH)2]2− were discussed based on optimizations at the B3LYP/3-21G level of theory, and simulated UV/Vis absorption spectra were obtained with the TD Hamiltonian

Use of a Hydrophobic Azo Dye for the Centrifuge-Less Cloud Point Extraction–Spectrophotometric Determination of Cobalt

The hydrophobic azo dye 6-hexyl-4-(2-thiazolylazo)resorcinol (HTAR, H2L) was studied as part of a system for the centrifuge-less cloud point extraction (CL-CPE) and spectrophotometric determination of traces of cobalt. The extracted 1:2 (Co:HTAR) complex, [CoIII(HL−)(L2−)]0, shows an absorption maximum at 553 nm and contains HTAR in two different acid–base forms. Optimum conditions for its formation and CL-CPE were found as follows: 1 × 10−5 mol L−1 of HTAR, 1.64% of Triton X-114, pH of 7.8, incubation time of 20 min at ca. 50 °C, and cooling time of 30 min at ca. −20 °C. The linear range, limit of detection, and apparent molar absorptivity coefficient were 5.4–189 ng mL−1, 1.64 ng mL−1, and 2.63 × 105 L mol−1 cm−1, respectively. The developed procedure does not use any organic solvents and can be described as simple, cheap, sensitive, convenient, and environmentally friendly. It was successfully applied to the analysis of artificial mixtures and real samples, such as steel, dental alloy, rainwater, ampoules of vitamin B12, and saline solution for intravenous infusion

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI) : a phase 3, placebo-controlled, randomised trial

Background: Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin. In this trial, we aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor. Methods: The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) was a phase 3 randomised, double-blinded, placebo-controlled trial, done in 1315 sites in 42 countries. Patients were eligible if 50 years or older, with type 2 diabetes, receiving anti-hyperglycaemic drugs for at least 6 months, with stable coronary artery disease, and one of three other mutually non-exclusive criteria: a history of previous PCI or of coronary artery bypass grafting, or documentation of angiographic stenosis of 50% or more in at least one coronary artery. Eligible patients were randomly assigned (1:1) to either ticagrelor or placebo, by use of an interactive voice-response or web-response system. The THEMIS-PCI trial comprised a prespecified subgroup of patients with previous PCI. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke (measured in the intention-to-treat population). Findings: Between Feb 17, 2014, and May 24, 2016, 11 154 patients (58% of the overall THEMIS trial) with a history of previous PCI were enrolled in the THEMIS-PCI trial. Median follow-up was 3·3 years (IQR 2·8–3·8). In the previous PCI group, fewer patients receiving ticagrelor had a primary efficacy outcome event than in the placebo group (404 [7·3%] of 5558 vs 480 [8·6%] of 5596; HR 0·85 [95% CI 0·74–0·97], p=0·013). The same effect was not observed in patients without PCI (p=0·76, p interaction=0·16). The proportion of patients with cardiovascular death was similar in both treatment groups (174 [3·1%] with ticagrelor vs 183 (3·3%) with placebo; HR 0·96 [95% CI 0·78–1·18], p=0·68), as well as all-cause death (282 [5·1%] vs 323 [5·8%]; 0·88 [0·75–1·03], p=0·11). TIMI major bleeding occurred in 111 (2·0%) of 5536 patients receiving ticagrelor and 62 (1·1%) of 5564 patients receiving placebo (HR 2·03 [95% CI 1·48–2·76], p<0·0001), and fatal bleeding in 6 (0·1%) of 5536 patients with ticagrelor and 6 (0·1%) of 5564 with placebo (1·13 [0·36–3·50], p=0·83). Intracranial haemorrhage occurred in 33 (0·6%) and 31 (0·6%) patients (1·21 [0·74–1·97], p=0·45). Ticagrelor improved net clinical benefit: 519/5558 (9·3%) versus 617/5596 (11·0%), HR=0·85, 95% CI 0·75–0·95, p=0·005, in contrast to patients without PCI where it did not, p interaction=0·012. Benefit was present irrespective of time from most recent PCI. Interpretation: In patients with diabetes, stable coronary artery disease, and previous PCI, ticagrelor added to aspirin reduced cardiovascular death, myocardial infarction, and stroke, although with increased major bleeding. In that large, easily identified population, ticagrelor provided a favourable net clinical benefit (more than in patients without history of PCI). This effect shows that long-term therapy with ticagrelor in addition to aspirin should be considered in patients with diabetes and a history of PCI who have tolerated antiplatelet therapy, have high ischaemic risk, and low bleeding risk